(Bloomberg) — Pfizer Inc. won't bring an over-the-counter version of its cholesterol pill Lipitor to the U.S. market, after a trial found that patients couldn't take the drug correctly without a doctor's help.
Pfizer's decision to kill the over-the-counter program ends a years-long effort designed to preserve sales of what was once the New York-based company's — and the world's — top-selling drug. Since losing patent protection in 2011, Lipitor's sales have fallen from more than $10 billion a year to $2.06 billion last year.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
